Identification of distinct phenotypes of locally advanced pancreatic adenocarcinoma

Journal of Gastrointestinal Cancer

Volumn 44, Issue 1, 2013, Pages 73-78

  Teo, Minyuen ^a   Crotty, Grace F ^b   O'Súilleabháin, Criostóir ^b   Ridgway, Paul F ^a   Conlon, Kevin C ^a   Power, Derek G ^b   McDermott, Ray S ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Biology; Chemotherapy; Natural history; Pancreatic neoplasm

Indexed keywords

CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COURSE EVALUATION; DISEASE COURSE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERITONEUM METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

EID: 84873716893     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-012-9419-9     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(18287387):71-96.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607-20. doi: 10.1016/S0140-6736(10)62307-0.
3. Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267. doi: 10.1371/journal.pmed.1000267.t008.
4. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007;96(8):1183-90. doi: 10.1038/sj.bjc.6603719.
5. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592-9. doi: 10.1093/annonc/mdn281.
6. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105-12. doi: 10.1200/JCO.2011.34.8904.
7. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806-13. doi: 10.1200/JCO.2008.17.7188.
8. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PWT, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496-502. doi: 10.1200/JCO.2007.15.8634.
9. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PWT, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3487-95. doi: 10.1200/JCO.2007.15.8642.
10. Shoup M, Winston C, Brennan MF, Bassman D, Conlon KC. Is there a role for staging laparoscopy in patients with locally advanced, unresectable pancreatic adenocarcinoma? J Gastrointest Surg. 2004;8(8):1068-71. doi: 10.1016/j.gassur.2004.09.026.
11. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25. doi: 10.1056/ NEJMoa1011923.
12. Hernandez JM, Morton CA, Al-Saadi S, Villadolid D, Cooper J, Bowers C, et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. Am Surg. 2010;76(5):480-5.
13. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA J Am Med Assoc. 2007;297(3):267-77. doi: 10.1001/jama.297.3.267.
14. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52-60. doi: 10.1097/01.sla.0000259391.84304.2b.
15. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35(6):600-4. doi: 10.1016/j.ejso.2008.12. 006.
16. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol. 1985;3(3):373-8.
17. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer. 1981;48(8):1705-10.
18. Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer. 1988;61(6):1110-6.
19. Whittington R, Solin L, Mohiuddin M, Cantor RI, Rosato FE, Biermann WA, et al. Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer. 1984;54(9):1991-8.
20. Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2011:n/a-n/a. doi:papers2://publication/ doi/ 10.1002/cncr.26633.
21. Azria D, Ychou M, Jacot W, Thezenas S, Lemanski C, Senesse P, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas. 2002;25(4):360-5.
22. Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, et al. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer. 2007;97(4):464-71. doi: 10.1038/sj.bjc.6603900.
23. Ben-Josef E, Lawrence TS. Radiotherapy: the importance of local control in pancreatic cancer. Nat Rev Clin Oncol. 2011;9(1):9-10.
24. Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol. 2011;11(1):123. doi: 10.1186/1471-230X-11-123.
25. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25(3):326-31. doi: 10.1200/JCO.2006.07.5663.
26. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500-3. doi: 10.1038/nm.2344.
27. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011. doi: 10.1200/JCO.2010.33.8038.